Symbols

RNXT

RenovoRx·NASDAQ

--(--)

RNXT fundamentals

RNXT Q4 2025 Earnings Preview

RenovoRx (RNXT) expects to report earnings on Mar 30, 2026, with estimated revenue of 419.70K (YoY +876.05%), and EPS at -0.08 (YoY +27.27%).

Revenue estimate / YoY

419.70K

+876.05%

EPS estimate / YoY

-0.08

+27.27%

Report date

Mar 30, 2026

RNXT Earnings Call Summary for Q4,2025

Leadership Evolution: Dr. Agah shifts to strategic role, CEO focuses on scaling, and CFO brings high-growth expertise.
2025 Financial Milestones: $1.1M revenue, 88% gross margin, and $10M private placement to fuel 2026 growth.
2026 Growth Plan: Target 36 commercial sites and $3-4M revenue, driven by 17 transitioning trial sites and 21 pipeline centers.
Clinical Momentum: 104/114 patients randomized in TIGeR-PaC trial, with final data in 2027.
Q1 2026 Outlook: Strongest quarter yet, with sequential growth expected throughout the year.

Earnings

EPS

Revenue

Revenue & Expenses

RNXT has released its 2025 Q4 earnings report, with revenue of 238.00K, reflecting a YoY change of 453.49%, and net profit of -2.94M, showing a YoY change of -2.19%. The Sankey diagram below clearly presents RNXT's revenue sources and cost distribution.

Key Indicators

RenovoRx (RNXT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

RenovoRx (RNXT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

RenovoRx (RNXT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

RenovoRx (RNXT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown